Skip to Main Content

Paper Details

A model of persistent post SARS-CoV-2 induced lung disease for target identification and testing of therapeutic strategies.
bioRxiv
6
2022
ARDS, COVID-19, EIDD-2801, Mouse, PASC, SARS-CoV-2, SARS-CoV-2 pulmonary disease, acute respiratory distress syndrome, alveolar intermediate cells, chronic inflammation, collagen, human, humans, lung abnormalities, lung disease, mice, nintedanib, post-acute sequelae, proliferative fibroblasts
Author NameAffiliation
Sarah R LeistUniversity of North Carolina at Chapel Hill
Kenichi OkudaMarsico Lung Institute, University of North Carolina at Chapel Hill
Rodney C GilmoreMarsico Lung Institute, University of North Carolina at Chapel Hill
Ande WestUniversity of North Carolina at Chapel Hill
Alexandra Sch??ferUniversity of North Carolina at Chapel Hill
Lisa E GralinskiUniversity of North Carolina at Chapel Hill
Lisa E GralinskiUniversity of North Carolina at Chapel Hill
Alain C Borczuk
Leigh ThorneUniversity of North Carolina at Chapel Hill
Wanda K O'NealMarsico Lung Institute, University of North Carolina at Chapel Hill
Stephanie A MontgomeryLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Stephanie A MontgomeryUniversity of North Carolina at Chapel Hill
Richard C BoucherMarsico Lung Institute, University of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
  • 1 - 19

Datasets

Release 1.2